Epigenetic Editing Tool for Targeting Hepatitis B Virus Gene
Summary
USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes, filed by inventors Wenbo Peng, Junzheng Zhao, Shaoshuai Mao, Leilei Wu, Di Sun, Ruimin Lv, Ying Zang, and Junjian Liu on December 4, 2025. The application covers compositions and methods for epigenetic modification of HBV genes for therapeutic use in biomedicine.
What changed
USPTO published patent application US20260097133A1 for an epigenetic editing tool targeting hepatitis B virus genes. The application covers methods and compositions for epigenetic modification of hepatitis B virus genes for therapeutic applications.
Implications: Researchers and companies developing hepatitis B therapies should monitor this application. The epigenetic editing technology claims could affect future HBV treatment development strategies and potential licensing opportunities.
What to do next
- Monitor USPTO database for patent status updates
- Review application claims for competitive intelligence
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
EPIGENETIC EDITING TOOL FOR TARGETING HEPATITIS B VIRUS GENE
Application US20260097133A1 Kind: A1 Apr 09, 2026
Inventors
Wenbo PENG, Junzheng ZHAO, Shaoshuai MAO, Leilei WU, Di SUN, Ruimin LV, Ying ZANG, Junjian LIU
Abstract
The present application relates to the field of biomedicine, and provides an epigenetic editing tool for targeting a hepatitis B virus gene and a use thereof.
CPC Classifications
A61K 48/005 A61K 9/127 A61K 9/5123 A61P 31/20 C12N 9/1007 C12N 9/226 C12N 15/111 C12N 15/86 C12N 15/88 C07K 2319/08 C07K 2319/81 C12N 2310/20 C12N 2750/14143 C12Y 201/01037
Filing Date
2025-12-04
Application No.
19409031
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.